Summary
Guardant Health, Inc. (GH) has filed an 8-K on February 19, 2026, to announce its financial results for the fiscal quarter and year ended December 31, 2025. The key details of these results are contained within a press release furnished as Exhibit 99.1 to the filing. Investors should refer to this press release for specific performance metrics, revenue figures, profitability, and any forward-looking guidance provided by the company. While the 8-K itself is a procedural filing, the accompanying press release is the critical document for understanding Guardant Health's recent financial performance and its outlook. Investors will be looking for information regarding the growth in their diagnostic testing volume, reimbursement trends, and progress in commercializing their liquid biopsy solutions for cancer detection and monitoring. Any updates on clinical trial progress or regulatory approvals for their products would also be highly relevant.
Key Highlights
- 1Guardant Health announced its financial results for the period ending December 31, 2025, via an 8-K filing.
- 2The full financial results and commentary are detailed in a press release furnished as Exhibit 99.1.
- 3Investors are directed to the Exhibit 99.1 press release for specific financial performance data.
- 4The filing includes results for both the fiscal quarter and the full fiscal year ended December 31, 2025.
- 5The information provided is furnished and not deemed 'filed' for certain regulatory purposes.
- 6The filing also includes the Cover Page Interactive Data File in XBRL format.